Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Then average down, no need to complain then.
Old saying about gravity? These are stocks man.
Of this is true should make this a sticky...
Its going the opposite way lol.
Hey, did I tell you it's still up 100% for the day....
Over 1 billion dollars thick.....
Why would a tangible asset be worth zero....yeah ok. Billion dollars of gold but mine is wortless.......
Read again good grief....says earliest transaction date.
Look at the signed dates on form 4 again. Wrong.....
How about actual numbers......proof of the accusation.
Yeah ok....what does doesn't add up even mean.
That was the point....geeesh. could be done for all we know.
"Since they don't hold onto them"
We know they sold 50% between sept and December. No idea how much left yet.
They sold 50% before December 31st.
The shares were only worth 2.4 mil at the time of agreement. FACT.
Can you tell me if they still hold any in the last 2.5 months???......guess we will move in to the next topic.
Incorrect...the share price was .02 back in September when the agreement was struck. So that is saying 122million was worth 2.4mil.
Half has already been converted as of December. Sounds like RBC made a good investment to me.
Thats mine....need some more.
Don't worry ill do the hard work. Another 2.5 second Google search.
https://www.google.com/amp/s/pubcoceo.com/2019/01/09/58-companies-uplist-from-the-otc-to-nasdaq-nyse-in-2018/amp/
This literally took 2.5 seconds on Google.
https://www.google.com/amp/s/www.thehindubusinessline.com/companies/torrent-pharma-acquires-usbased-generic-otc-player-biopharm/article10040237.ece/amp/
So, what reverence does that have to his post?
Thats fine. Our market cap is severely undervalued.
It was updated numbers as of end of December. No idea what share structure was 5 months ago. Last quarterly was almost 6 months ago.
All I know is I'm good with 380million right now.
Huh.... what are you talking about. Its dated Jan 28, 2021. The balance of the note in question is clear as day.
You sir are incorrect....go read the OTCQB certification dated December 31st. Look at the bottom.......
https://www.otcmarkets.com/stock/SBFM/disclosure
Your welcome.
Already 50% converted as of 2 months ago.
Wow 50% done as of the certification date. Wonder why that was never brought up today...
Their is a reason SBFM has gained so much attention this weekend...
As an OTC whole yes. But the people that have positive bank accounts are able to separate the diamonds from the trash....So I believe their is upside here vs downside.
Thanx man, saved me the time of looking it up.
Is that what they are doing at university or Georgia, just renting a classroom?
I see $122,000 note for 2 million in financing. You said 80 million shares left?
I saw thanx. This accused during the reported quarter and the .001 term is not on the report.
Those terms are not in the quarterly. Which was during this time frame.
Please cut and paste just like I did. Where does it say they took over that note. My info is straight from quarterly.
That 2 million RBC dollars is completely separate. These are the terms from the quarterly.
n September 8, 2020, the Company executed a Financing Agreement with RB Capital Partners, Inc., La Jolla, CA, who has agreed to provide the
Company with a minimum of $2 million in convertible debt financing over the next three to six months pursuant to the terms and conditions included
in relevant Promissory Notes (the “Promissory Notes”). The Promissory Notes will bear interest at the rate of 5% per annum and will be fully
convertible into shares of shares of the Company’s Common Stock at a conversion price equal to the market value of the Company’s Common Stock
on the applicable conversion date or $0.30 per share, whichever is greater. The Promissory Notes will have a maturity date of two years from the date
of issuance and must be fully converted on or before the maturity date. The Company has the right under these Promissory Notes to pay off all or any
part of the Promissory Notes at any time without penalty.
The CEO owns that note your talking about. What are you No way that RBC loan converts to 2billion shares. That 280million dollars at this price.
That note is held by the CEO. Since they just issued themselves shares I'm going to assume it will be cleared up shortly.
A Note Payable dated December 31, 2018 held by the CEO of the Company having a Face Value of $117,535 Canadian ($86,118 US) and accruing
interest at 12% was due December 31, 2019. On December 31, 2019, the Company renewed the Note together with accrued interest of $14,104
Canadian ($10,845 US) and cash advances made to the Company of $36,473 Canadian ($28,044 US) for a 12-month period. The new Note, which
was converted to USD, now has a face Value of $128,269 US. This new Note is nonconvertible, accrues interest at 12% per annum and has a maturity
date of December 31, 2020.
How are you coming up with those numbers? RBC hasn't even given the 2 million yet. 100 million shares at this price is 98million dollars, yeah OK buddy.
2 million dollar loan converted at .001 would be 2 billion shares. Thats 280million dollars at current price.
Like I said, that conversion price wasn't on the more recent quarterly report. But I shot an email off to just clarify.
You are correct. The quarterly report was published a whole month after that 8k. Thank you for confirming the most resent parameters of the loan.
I laughed so hard I almost spit my food out....filing complaints against the company, havnt heard that one before. Good grief
From the annual report.
On September 8, 2020, we executed a Financing Agreement with RB Capital Partners, Inc., La Jolla, CA, who has agreed to provide us with a minimum of $2 million in convertible debt financing over the next three to six months pursuant to the terms and conditions included in relevant Promissory Notes (the “Promissory Notes”). As of September 30, 2020, we have received a total of $300,000 in funding under this agreement.
The Promissory Notes will bear interest at the rate of 5% per annum and will be fully convertible into shares of our Common Stock at a conversion price equal to the market value of our Common Stock on the applicable conversion date or $0.30 per share, whichever is greater. The Promissory Notes will have a maturity date of two years from the date of issuance and must be fully converted on or before the maturity date. We have the right under these Promissory Notes to pay off all or any part of the Promissory Notes at any time without penalty.
We intend to use the proceeds from this financing for development of our recently announced Coronavirus treatment on a priority basis and the clinical development of Adva-27a, our flagship anticancer compound targeted for pancreatic cancer.
From annual report dated Nov 10th
On September 8, 2020, we executed a Financing Agreement with RB Capital Partners, Inc., La Jolla, CA, who has agreed to provide us with a minimum of $2 million in convertible debt financing over the next three to six months pursuant to the terms and conditions included in relevant Promissory Notes (the “Promissory Notes”). As of September 30, 2020, we have received a total of $300,000 in funding under this agreement.
The Promissory Notes will bear interest at the rate of 5% per annum and will be fully convertible into shares of our Common Stock at a conversion price equal to the market value of our Common Stock on the applicable conversion date or $0.30 per share, whichever is greater. The Promissory Notes will have a maturity date of two years from the date of issuance and must be fully converted on or before the maturity date. We have the right under these Promissory Notes to pay off all or any part of the Promissory Notes at any time without penalty.
We intend to use the proceeds from this financing for development of our recently announced Coronavirus treatment on a priority basis and the clinical development of Adva-27a, our flagship anticancer compound targeted for pancreatic cancer.